Keywords: EMEA. CHMP, Novartis, Lucentis, Bristol-Myers Squibb, Sprycel, Pfizer, Sutent, AstraZeneca, FLUENZInfluenza, Genzyme, Fabrazyme

Europe’ CHMP extends use for Novartis’ Lucentis, B-MS’s Sprycel and Pfizer’s Sutent; backs AstraZeneca’s FLUENZInfluenza vaccine; updates on Fabrazyme

Article | 25 October 2010

Print This

At its meetings last week, the European Medicines Agency's (EMEA) Committee for Medicinal Products for Human Use (CHMP) issued a ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in